Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A
3(75.0%)
Early Phase 1
1(25.0%)
4Total
N/A(3)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07490951Not ApplicableNot Yet Recruiting

Cluster of Differentiation 19 (CD19)/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Refractory Autoimmune Diseases

Role: lead

NCT07333196Not Yet Recruiting

Tongji NADs Cohort

Role: collaborator

NCT07336823Early Phase 1Recruiting

JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma

Role: lead

NCT06890065Not ApplicableRecruiting

JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia

Role: lead

NCT06678282Not ApplicableRecruiting

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

Role: lead

All 5 trials loaded